DISCLAIMERThe information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.
email sent successfully
|You are receiving this because you have an account on www.oneGRAVESvoice.com|
|To unsubscribe from these emails, click here|
Trusted Resources: News & Meetings
Latest announcements and gatherings
Teprotumumab Significantly Improves Proptosis in Thyroid eye Disease
Patients with thyroid eye disease treated with teprotumumab demonstrated a significant reduction in proptosis compared with those treated with placebo, according to phase 3 results from the OPTIC trial.
The ideal treatment for thyroid eye disease would decrease inflammation, reduce proptosis and double vision, improve quality of life, have minimal adverse effects and minimize the need for surgical treatment, Raymond S. Douglas, MD, PhD, director of the orbital and thyroid eye disease program at Cedars-Sinai Medical Center, said in a presentation on the topic at Hawaiian Eye 2020.
Additionally, this treatment would target the long-term manifestations of the disease rather than the short-term manifestations that are primarily targeted with steroids and other second line agents, he said.
More from Teprotumumab News:
Clinical Trial Analyses Substantiate that Teprotumumab Improves Debilitating Effects of TED
FDA Grants Priority Review of Teprotumumab Biologics License Application for the Treatment of TED
More from Teprotumumab Research:
Teprotumumab for the Treatment of Active Thyroid Eye Disease
(Authors: Raymond S. Douglas, George J. Kahaly et. al.)
Teprotumumab in the Treatment of Active TED: A Focus on Proptosis
(Author: Raymond S. Douglas)
Evidence & EducationThyroid Eye DisordersWhat is the Thyroid? The thyroid is a b...
Evidence & EducationQuality of Life Improves After Strabismus Surgery in Patients With Graves’ OrbitopathyObjective: To evaluate the influence of...
Evidence & EducationOrbital Decompression for Thyroid Eye Disease: Methods, Outcomes, and ComplicationsPurpose: To determine the safety and ef...
News & MeetingsHorizon Pharma plc Announces Phase 3 Confirmatory Trial Evaluating Teprotumumab (OPTIC) for the Treatment of Active ...Horizon Pharma plc today announced topli...
Evidence & EducationManejo Quirúrgico de la Enfermedad de Graves• La tiroidectomía puede considerarse...
Evidence & EducationWhich Factors are Associated With Quality of Life in Patients With Graves’ Orbitopathy Presenting for Orbital ...Purpose: Graves' orbitopathy (GO) is as...
News & MeetingsHorizon Therapeutics Announces the FDA has Granted Priority Review of the Teprotumumab Biologics License Application...Horizon Therapeutics plc today announced...
send a message
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.